PBF 1129
Alternative Names: PBF-1129Latest Information Update: 17 Jul 2023
Price :
$50 *
At a glance
- Originator Palobiofarma
- Developer Ohio State University; Palobiofarma
- Class Antifibrotics; Antineoplastics
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 17 Jul 2023 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (PO) prior to July 2023 (Palobiofarma pipeline, July 2023)
- 10 Feb 2022 National Cancer Institute plans a phase I trial for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Recurrent) in USA (PO) by April 2022 (NCT05234307)
- 06 Jan 2022 Phase-I clinical trials in Idiopathic pulmonary fibrosis in Spain (PO) (Palobiofarma pipeline, January 2022)